Company News

New opportunity for Oxford Vacmedix future clinical development through sale of Head of Clinical Operations, Mark Thomas’ company Clinicology Ltd.

Company News /

FGK Clinical Research GmbH, announces the successful acquisition of Clinicology Ltd. This strategic move marks a significant milestone for both companies and benefits OVM Oxford, UK – 4th March 2024 Press Release – Sale of Clinicology Ltd. Oxford Vacmedix (OVM), the clinical stage company developing therapeutic cancer vaccines, announced today that Clinicology Ltd, the contract […]

New opportunity for Oxford Vacmedix future clinical development through sale of Head of Clinical Operations, Mark Thomas’ company Clinicology Ltd. Read More »

Oxford Vacmedix team support new University of Oxford educational initiative

Company News /

The team at Oxford Vacmedix contribute to the design and the delivery of a novel MSc course in Applied Cancer Science being run by the Department of Oncology at the University of Oxford Oxford, UK – 26th February 2024 Press Release – Oxford Vacmedix support new University of Oxford educational initiative Oxford Vacmedix (OVM), the

Oxford Vacmedix team support new University of Oxford educational initiative Read More »

Oxford Vacmedix announces major milestone in clinical development of OVM-200

Company News /

OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable three years post manufacture – a major milestone for OVM’s lead cancer vaccine, OVM-200 Oxford, UK – 31st January 2024 Press Release – OVM-200 major milestone three year stabilty Oxford Vacmedix (OVM), the clinical stage company developing therapeutic cancer vaccines, announced today

Oxford Vacmedix announces major milestone in clinical development of OVM-200 Read More »

Licensing deal with Dx&Vx for OVM-200 in South Korea and China

Company News /

Ongoing discussions at an advanced stage with leading shareholder DxVx, to license OVM-200 for South Korea and for China. Oxford, UK – 28th November 2023 Press Release – Licensing deal with Dx&Vx for OVM-200 in South Korea and China Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer announced today ongoing licensing

Licensing deal with Dx&Vx for OVM-200 in South Korea and China Read More »

New publication highlights importance of survivin as target and potential for combination use to treat cancer

Company News, Publications /

A new publication in Advanced Therapeutics comprehensively reviews the rationale and preclinical results for OVM-200 both alone and in combination. Oxford, UK – 10th October 2023 Press Release – Importance of Survivin as a target and potential for combination use to treat cancer Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of

New publication highlights importance of survivin as target and potential for combination use to treat cancer Read More »

Oxford Vacmedix feature in ‘Advancing Immunology’

Company News /

Oxford Vacmedix to feature in ITN Business’ programme ‘Advancing Immunology’ – exploring the use of new technology to develop vaccines to treat cancer Oxford, UK – 26th May 2023 ITN Business present Oxford Vacmedix in a new series on ‘Advancing Immunology’. The programme explores how cancer therapeutic vaccines are being trialled and could reduce the

Oxford Vacmedix feature in ‘Advancing Immunology’ Read More »

Oxford Vacmedix announces major manufacturing milestone for OVM-200

Company News /

OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable two years post manufacture – a major milestone for OVM’s lead cancer vaccine development Oxford, UK – 12th May 2023 Press Release – Oxford Vacmedix announces major manufacturing milestone for OVM-200 Oxford Vacmedix (OVM), the UK-based biopharma company developing therapeutic cancer vaccines,

Oxford Vacmedix announces major manufacturing milestone for OVM-200 Read More »

Oxford Vacmedix sponsors MRC i-Case studentship at University of Oxford

Company News /

New appointment In Professor Shisong Jiang’s research group in the Department of Oncology brings further expertise to research applications for Recombinant Overlapping Peptides (ROPs) Oxford, UK – 5th April 2023 Press Release – Oxford Vacmedix sponsors MRC i-Case studentship at University of Oxford Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of

Oxford Vacmedix sponsors MRC i-Case studentship at University of Oxford Read More »

Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200

Company News /

The initial part of a Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been completed – the first clinical trial of a cancer vaccine using novel ROP technology. Oxford, UK – 29th March 2023 Press Release – Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200

Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200 Read More »

OVM-200 Phase 1 Clinical Trial featured on TV

Company News /

The OVM-200 Phase 1 Clinical Trial at The Christie in Manchester was featured on ITV’s Granada News on Wednesday 7th September 2022. It is a first-in-class of ROP cancer vaccine in human clinical trial. ROP therapeutic vaccines will provide additional options for the treatment of cancer patients. Professor Shisong Jiang, Chief Scientific Officer and Founder

OVM-200 Phase 1 Clinical Trial featured on TV Read More »